• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

活细胞中的高保真和差异无义抑制以及携带人类转运RNA的额颞叶痴呆等位基因。

High-fidelity and differential nonsense suppression in live cells and a frontotemporal dementia allele with human transfer RNAs.

作者信息

Beharry Aruun, Ward Cian, Moore Henry, Hoffman Kyle S, Chan Patricia P, Lowe Todd M, O'Donoghue Patrick

机构信息

Department of Biochemistry, The University of Western Ontario, London, Ontario, N6A 5C1, Canada.

Department of Biomolecular Engineering, Baskin School of Engineering & UCSC Genomics Institute, University of California Santa Cruz, Santa Cruz, CA 95064, United States.

出版信息

Nucleic Acids Res. 2025 Jul 19;53(14). doi: 10.1093/nar/gkaf730.

DOI:10.1093/nar/gkaf730
PMID:40794874
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12361112/
Abstract

Nonsense mutations generate premature termination codons (PTCs) that are responsible for 11% of genetic disease alleles. The arginine (Arg, CGA) to stop (UGA) mutation is the most common PTC. Humans encode >600 transfer RNA (tRNA) genes with many identical and similar copies. We developed a dual fluorescent reporter to quantify PTC readthrough in live cells and found single nucleotide mutations of human tRNAArg gene variants enabled differential nonsense suppression that depended on the tRNA sequence and the cell type. We investigated G36A variants of all six human tRNAArgUCG isodecoders, and only the TCG-6-1 tRNA, where G36A occurs in 0.01% of human genomes, was unable to translate nonsense codons. With tRNA sequencing, we showed that a suppressor tRNA derived from the TCG-3-1 gene was expressed 2.1-fold higher and generated 1.8-fold more nonsense suppression than a tRNA derived from the TCG-4-1 gene. In a neuroblastoma model of frontotemporal dementia, we observed >70% readthrough of progranulin R493X with a suppressor tRNA that represented 5%-18% of the total tRNAArg pool. The tRNAs outperformed aminoglycoside-induced nonsense suppression in efficacy, tolerability to the cells, and translation fidelity according to mass spectrometry. Our studies show that human nonsense suppressor tRNAs can correct genetic defects that cause disease.

摘要

无义突变会产生过早终止密码子(PTC),这些密码子导致了11%的遗传疾病等位基因。精氨酸(Arg,CGA)突变为终止密码子(UGA)是最常见的PTC。人类编码超过600个转移RNA(tRNA)基因,其中有许多相同和相似的拷贝。我们开发了一种双荧光报告基因来定量活细胞中的PTC通读情况,发现人类tRNAArg基因变体的单核苷酸突变能够实现差异无义抑制,这取决于tRNA序列和细胞类型。我们研究了所有六种人类tRNAArgUCG同功受体的G36A变体,只有TCG-6-1 tRNA(在0.01%的人类基因组中发生G36A突变)无法翻译无义密码子。通过tRNA测序,我们发现源自TCG-3-1基因的抑制性tRNA表达量高2.1倍,产生的无义抑制比源自TCG-4-1基因的tRNA多1.8倍。在额颞叶痴呆的神经母细胞瘤模型中,我们观察到携带一种抑制性tRNA时,前颗粒蛋白R493X的通读率超过70%,该抑制性tRNA占总tRNAArg池的5%-18%。根据质谱分析,这些tRNA在疗效、对细胞的耐受性和翻译保真度方面优于氨基糖苷诱导的无义抑制。我们的研究表明,人类无义抑制性tRNA可以纠正导致疾病的遗传缺陷。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/7ad36a6367ba/gkaf730fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/9930ad8247e9/gkaf730figgra1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/9c48dec88b46/gkaf730fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/b724be5a4f85/gkaf730fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/76fd2e5224cb/gkaf730fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/ac3834f7e63b/gkaf730fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/b9644650fa81/gkaf730fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/63f212d30f77/gkaf730fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/11b737e641f9/gkaf730fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/7ad36a6367ba/gkaf730fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/9930ad8247e9/gkaf730figgra1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/9c48dec88b46/gkaf730fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/b724be5a4f85/gkaf730fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/76fd2e5224cb/gkaf730fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/ac3834f7e63b/gkaf730fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/b9644650fa81/gkaf730fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/63f212d30f77/gkaf730fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/11b737e641f9/gkaf730fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b7/12361112/7ad36a6367ba/gkaf730fig8.jpg

相似文献

1
High-fidelity and differential nonsense suppression in live cells and a frontotemporal dementia allele with human transfer RNAs.活细胞中的高保真和差异无义抑制以及携带人类转运RNA的额颞叶痴呆等位基因。
Nucleic Acids Res. 2025 Jul 19;53(14). doi: 10.1093/nar/gkaf730.
2
An engineered glutamic acid tRNA for efficient suppression of pathogenic nonsense mutations.一种用于有效抑制致病性无义突变的工程化谷氨酸转运RNA。
Nucleic Acids Res. 2025 Jun 20;53(12). doi: 10.1093/nar/gkaf532.
3
Suppressor tRNA in gene therapy.抑制 tRNA 在基因治疗中的作用。
Sci China Life Sci. 2024 Oct;67(10):2120-2131. doi: 10.1007/s11427-024-2613-y. Epub 2024 Jun 24.
4
ACE-tRNAs are a platform technology for suppressing nonsense mutations that cause cystic fibrosis.ACE-tRNA是一种用于抑制导致囊性纤维化的无义突变的平台技术。
Nucleic Acids Res. 2025 Jul 8;53(13). doi: 10.1093/nar/gkaf675.
5
Nonsense Mutations in Rare and Ultra-Rare Human Disorders: An Overview.罕见和超罕见人类疾病中的无义突变:概述
IUBMB Life. 2025 Jun;77(6):e70031. doi: 10.1002/iub.70031.
6
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.用于治疗囊性纤维化的阿他芦醇及类似化合物(针对I类提前终止密码子突变的特定疗法)。
Cochrane Database Syst Rev. 2017 Jan 19;1(1):CD012040. doi: 10.1002/14651858.CD012040.pub2.
7
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.依伐卡托(Ataluren)及类似化合物(针对 I 类提前终止密码子突变的特异性治疗药物)治疗囊性纤维化。
Cochrane Database Syst Rev. 2023 Mar 3;3(3):CD012040. doi: 10.1002/14651858.CD012040.pub3.
8
Developing AAV-delivered nonsense suppressor tRNAs for neurological disorders.开发用于神经疾病的 AAV 递送的无义抑制 tRNA。
Neurotherapeutics. 2024 Jul;21(4):e00391. doi: 10.1016/j.neurot.2024.e00391. Epub 2024 Jul 2.
9
Emerging Personalized Opportunities for Enhancing Translational Readthrough in Rare Genetic Diseases and Beyond.新兴的个性化机会,用于增强罕见遗传疾病及其他疾病的翻译通读。
Int J Mol Sci. 2023 Mar 23;24(7):6101. doi: 10.3390/ijms24076101.
10
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险

本文引用的文献

1
An engineered glutamic acid tRNA for efficient suppression of pathogenic nonsense mutations.一种用于有效抑制致病性无义突变的工程化谷氨酸转运RNA。
Nucleic Acids Res. 2025 Jun 20;53(12). doi: 10.1093/nar/gkaf532.
2
Optimization of ACE-tRNAs function in translation for suppression of nonsense mutations.优化用于抑制无义突变的翻译过程中ACE-tRNA的功能。
Nucleic Acids Res. 2024 Dec 11;52(22):14112-14132. doi: 10.1093/nar/gkae1112.
3
Mechanisms and Delivery of tRNA Therapeutics.tRNA 治疗药物的作用机制与递送。
Chem Rev. 2024 Jun 26;124(12):7976-8008. doi: 10.1021/acs.chemrev.4c00142. Epub 2024 May 27.
4
Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results.颗粒蛋白前体 AAV 基因治疗额颞叶痴呆:转化研究和 1/2 期试验中期结果。
Nat Med. 2024 May;30(5):1406-1415. doi: 10.1038/s41591-024-02973-0. Epub 2024 May 14.
5
Mistranslating the genetic code with leucine in yeast and mammalian cells.在酵母和哺乳动物细胞中用亮氨酸错译遗传密码。
RNA Biol. 2024 Jan;21(1):1-23. doi: 10.1080/15476286.2024.2340297. Epub 2024 Apr 17.
6
Translation velocity determines the efficacy of engineered suppressor tRNAs on pathogenic nonsense mutations.翻译速度决定了工程化抑制 tRNA 对致病性无义突变的疗效。
Nat Commun. 2024 Apr 5;15(1):2957. doi: 10.1038/s41467-024-47258-9.
7
Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development.促进过早终止密码子通读的药物:开发进展。
Biomolecules. 2023 Jun 14;13(6):988. doi: 10.3390/biom13060988.
8
Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia.拉托昔单抗,一种新型升高颗粒蛋白前体疗法,用于治疗额颞叶痴呆。
J Transl Med. 2023 Jun 15;21(1):387. doi: 10.1186/s12967-023-04251-y.
9
Balancing Nonsense Mutation Readthrough and Toxicity of Designer Aminoglycosides for Treatment of Genetic Diseases.平衡用于治疗遗传疾病的设计氨基糖苷类药物的无义突变通读与毒性
ACS Med Chem Lett. 2023 Apr 27;14(6):794-801. doi: 10.1021/acsmedchemlett.3c00089. eCollection 2023 Jun 8.
10
Engineered tRNAs suppress nonsense mutations in cells and in vivo.工程化 tRNA 可在细胞内和体内抑制无义突变。
Nature. 2023 Jun;618(7966):842-848. doi: 10.1038/s41586-023-06133-1. Epub 2023 May 31.